Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1071-1076

  Wu, Qian ^a   Zhuang, Gui Hua ^a   Wang, Xue Liang ^a   Hou, Tie Jun ^b   Shah, Dimpy P ^c   Wei, Xiao Li ^b   Wang, Li Rong ^a   Zhang, Min ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Xi'an Center for Disease Control and Prevention   (China)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anamnestic response; Anti HBs; HBV; Hepatitis B; Immune response; clinical trial; Long term; PDV; Plasma derived vaccine; Vaccine; Vaccine intervention study

Indexed keywords

HEPATITIS B VACCINE; HOST FACTOR;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; COMPARATIVE STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOGENICITY; LONG TERM CARE; NORMAL HUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; SEROCONVERSION; SEROLOGY; VACCINATION;

CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; LONGITUDINAL STUDIES; MALE;

EID: 84866062223     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20656     Document Type: Article

References (24)

1. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64; PMID:17714836; http://dx.doi.org/10.1016/j.vaccine.2007.06.059.
2. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al.; Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855-9; PMID:9197213; http://dx.doi.org/10.1056/NEJM199706263362602.
3. Lin HH, Wang LY, Hu CT, Huang SC, Huang LC, Lin SS, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003; 69:471-4; PMID:12601753; http://dx.doi.org/10.1002/jmv.10333.
4. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-26; PMID:18444799; http://dx.doi.org/10.1086/587695.
5. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-35; PMID:16652281; http://dx.doi.org/ 10.1086/503433.
6. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056.
7. Elavia AJ, Marfatia SP, Banker DD. Immunization of hospital personnel with low-dose intradermal hepatitis B vaccine. Vaccine 1994; 12:87-90; PMID:8303946; http://dx.doi.org/10.1016/0264-410X(94)90015-9.
8. Egemen A, Aksit S, Kurugöl Z, Erensoy S, Bilgiç A, Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 1998; 16:1511-5; PMID:9711797; http://dx.doi.org/10.1016/ S0264-410X(98)80006-6.
9. Duval B, Boulianne N, De Serres G, Laflamme N, De Wals P, Massé R, et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 2000; 18:1467-72; PMID:10618544; http://dx.doi. org/10.1016/S0264-410X(99)00422-3.
10. Goh KT, Tan KL, Kong KH, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull World Health Organ 1992; 70:233-9; PMID:1600584.
11. Chiaramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Renzulli G, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996; 14:135-7; PMID:8852410; http://dx.doi.org/10.1016/0264-410X(95)00148-T.
12. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri- Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010; 28:623-31; PMID:19887132; http://dx.doi.org/10.1016/j.vaccine. 2009.10.068.
13. ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine 2003; 21:3179-85; PMID:12804846; http://dx.doi.org/10.1016/ S0264-410X(03)00232-9.
14. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16:12-7; PMID:7742331; http://dx.doi.org/10.1016/1054-139X(94)00105-N.
15. Xu HW, Zhuang GH, Wang XL, Chen QJ, Chen ZJ. Efficacy and immune memory of plasmaderived hepatitis B vaccine 11 years after primary immunization. Chin J Prev Med 2000; 34:113-5.
16. Möst J, Larcher C, Vogetseder W, Prodinger WM, Huemer HP, Ebenbichler CF, et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine 1992; 10:740-1; PMID:1308114; http://dx.doi. org/10.1016/0264-410X(92)90507-G.
17. Chiaramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Renzulli G, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996; 14:135-7; PMID:8852410; http://dx.doi.org/10.1016/0264-410X(95)00148-T.
18. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6; PMID:19785526; http://dx.doi.org/10.1086/606119.
19. But DY, Lai CL, Lim WL, Fung J, Wong DKH, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26:6587-91; PMID:18835318; http://dx.doi.org/10.1016/j.vaccine. 2008.09.034.
20. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14(Suppl 1):6-10; PMID:17958636.
21. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-45; PMID:9392700; http://dx.doi. org/10.1056/NEJM199712113372406.
22. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003; 187:134-8; PMID:12508157; http://dx.doi.org/10.1086/345871.
23. Xu HW, Li DS, Xu JW, Zhuang GH, Wang XL. Evaluation of long-term efficacy on plasma-derived hepatitis B vaccine. Chin J Epidemiol 1992; 13: 362-365; PMID: 1303319.
24. Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, Zhang M. Antibody levels and immune memory 23 years after primary plasmaderived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011; 29(12): 2302-2307; PMID: 21277403; http://dx.doi.org/10.1016/ j.vaccine. 2011. 01.025.